Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA)

• ClinicalTrials.gov Identifier: NCT04906395
• Recruitment Status: Recruiting
• First Posted: May 28, 2021
• Last Update Posted: May 8, 2024
• Sponsor: Tolmar Inc.
• Information provided by (Responsible Party): Tolmar Inc.

Tracking Information

• First Submitted Date: May 12, 2021
• First Posted Date: May 28, 2021
• Last Update Posted Date: May 8, 2024
• Actual Study Start Date: July 1, 2021
• Estimated Primary Completion Date: April 30, 2025 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 27, 2022)

Suppression of ovarian function [ Time Frame: 6 weeks after the first administration of TOL2506 ]

LH level < 4 IU/L at Week 6

Original Primary Outcome Measures (submitted: May 24, 2021)

Suppression of ovarian function (E2 levels and menses status) [ Time Frame: 6 weeks after the first administration of TOL2506 ]

E2 levels < 20 pg/mL at Week 6 and absence of menses after Week 5

Current Secondary Outcome Measures (submitted: January 27, 2022)

• Suppression of ovarian function overall (LH, E2, menses; treatments pooled) [ Time Frame: Week 6 to Week 48 ]
  Percent of all subjects with LH < 4 IU/L, E2 <20 pg/mL in subjects treated with TOL2506 + endocrine therapy (tamoxifen or aromatase inhibitors) at every measurement from Week 6 to Week 48
• Suppression of ovarian function overall (LH, E2, menses; TOL2506 + tamoxifen) [ Time Frame: Week 6 to Week 48 ]
  Percent of all subjects with LH < 4 IU/L, E2 <20 pg/mL in subjects treated with TOL2506 + tamoxifen at every measurement from Week 6 to Week 48
• Suppression of ovarian function overall (LH, E2; TOL2506 + aromatase inhibitor) [ Time Frame: Week 6 to Week 48 ]
  Percent of all subjects with LH < 4 IU/L, E2 <20 pg/mL in subjects treated with TOL2506 + aromatase inhibitor at every measurement from Week 6 to Week 48

Original Secondary Outcome Measures (submitted: May 24, 2021)

• Suppression of ovarian function overall (E2 and absence of menses; treatments pooled) [ Time Frame: Week 6 to Week 48 ]
  Percent of subjects with suppressed E2 and absence of menses in subjects treated with TOL2506 + endocrine therapy (tamoxifen or aromatase inhibitors) at every measurement from Week 6 to Week 48
• Suppression of ovarian function overall (E2 and absence of menses; TOL2506 + tamoxifen) [ Time Frame: Week 6 to Week 48 ]
  Percent of subjects with suppressed E2 and absence of menses in subjects treated with TOL2506 + tamoxifen at every measurement from Week 6 to Week 48
• Suppression of ovarian function overall (E2 and absence of menses; TOL2506 + aromatase inhibitor) [ Time Frame: Week 6 to Week 48 ]
  Percent of subjects with suppressed E2 and absence of menses in subjects treated with TOL2506 + aromatase inhibitor at every measurement from Week 6 to Week 48
• Suppression of ovarian function at Weeks 12, 24, 36, and 48 (E2 and absence of menses + treatments pooled) [ Time Frame: Weeks 12, 24, 36, and 48 ]
  Percent of subjects with suppressed E2 < 20 pg/mL and absence of menses in subjects treated with TOL2506 + endocrine therapy (tamoxifen or aromatase inhibitors) assessed individually at weeks 12, 24, 36 and 48
• Suppression of ovarian function at Weeks 12, 24, 36, and 48 (E2 and absence of menses; TOL2506 + tamoxifen) [ Time Frame: Weeks 12, 24, 36, and 48 ]
  Percent of subjects with suppressed E2 < 20 pg/mL and absence of menses in subjects treated with TOL2506 + tamoxifen assessed individually at weeks 12, 24, 36 and 48
• Suppression of ovarian function at Weeks 12, 24, 36, and 48 (E2 and absence of menses; TOL2506 + aromatase inhibitor) [ Time Frame: Weeks 12, 24, 36, and 48 ]
  Percent of subjects with suppressed E2 < 20 pg/mL and absence of menses in subjects treated with TOL2506 + aromatase inhibitor assessed individually at weeks 12, 24, 36 and 48

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
• Official Title: Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
• Brief Summary: This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The study will also aim to assess the safety of TOL2506 in men with HR+, HER2-negative breast cancer. The Screening Period will be conducted in two parts: 1) an abbreviated, initial screening where premenopausal status will be determined prior to neoadjuvant or adjuvant chemotherapy (if planned) and 2) the full screening assessment conducted after neoadjuvant or adjuvant chemotherapy (or for subjects who enter the study without having received chemotherapy). Following the Screening Period, eligible subjects will enter into the 48 week Treatment Period in 1 of 2 groups: those who will receive tamoxifen concurrently with TOL2506 or those who will initiate therapy with an AI (letrozole, anastrozole, or exemestane) beginning 6 weeks after the first administration of TOL2506, upon confirmation that estradiol (E2) levels of < 20 pg/mL (testosterone levels < 50 ng/dL in males) have been achieved. After Week 12, subjects will be allowed to switch from receiving an AI to receiving tamoxifen or from tamoxifen to AI at the discretion of the Investigator. However, a switch is not permitted 28 days prior to a dosing visit (eg, Week 24, 36, and 48 where a pre-dose blood sample for PK and PD analysis will be drawn). At the end of the Treatment Period, upon completion of the End of Study Visit (Visit 9, Week 48) subjects may be eligible to participate in a Safety Extension Study under a separate Protocol.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Breast Cancer

Intervention

• Drug: TOL2506
  Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.
• Drug: Tamoxifen
  20 mg once daily or 10 mg 2 times daily - either tablet or solution
• Drug: Letrozole Tablets
  One 2.5 mg tablet taken orally once daily
• Drug: Anastrozole Tablets
  One 1 mg tablet taken orally once daily
• Drug: Exemestane Tablets
  One 25 mg tablet taken orally once daily

Study Arms

Experimental: Active Comparator: TOL2506

TOL2506 in combinatination with standard endocrine therapy (Tamoxifen & Aromatase Inhibitors)

Interventions:

• Drug: TOL2506
• Drug: Tamoxifen
• Drug: Letrozole Tablets
• Drug: Anastrozole Tablets
• Drug: Exemestane Tablets

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: May 24, 2021): 250
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: April 30, 2025
• Estimated Primary Completion Date: April 30, 2025 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

Female

1. Able to understand the investigational nature of this study and provide written informed consent prior to the participation in the trial
2. Age 18 to 49, inclusive
3. Diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer (ER>1% and/or, PR>1%, HER2-negative per ASCO CAP guidelines)
4. Is a candidate for endocrine therapy + ovarian suppression LH > 4 IU/L within 28 days prior to Day 1

5. Is premenopausal as defined by:

   • E2 > 30 pg/mL
   • follicle stimulating hormone (FSH) < 40 IU/L
   • regular menses (eg, menstrual cycle length of 21 to 35 days) Note: premenopausal status must be determined before neo/adjuvant chemotherapy in patients for which it is planned or prior to Day 1 in patients who did not have prior chemotherapy. If premenopausal status was not determined prior to chemotherapy, E2 and FSH must meet the above criteria when measured 2 weeks or more after the end of the final cycle of chemotherapy.

Exclusion Criteria:

1. Body mass index (BMI) < 18.00 kg/m2 or > 35.00 kg/m2
2. Breastfeeding
3. Life expectancy < 12 months
4. Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3

5. Unacceptable hepatic function as determined by any of the following:

   1. Alanine aminotransferase (ALT) ≥ 2X upper limit of normal (ULN)
   2. Aspartate aminotransferase (AST) ≥ 2X ULN
   3. Bilirubin ≥ 2X ULN
   4. Alkaline phosphatase ≥ 2X ULN
   5. Severe hepatic impairment (Child-Pugh Class C)

6. Unacceptable renal function as determined by any of the following:

   1. Creatinine ≥ 3X ULN
   2. Creatinine clearance ≤ 30 mL/minute
   3. Creatinine clearance ≤ 60 mL/minute in subjects with bone density 1.5 standard deviations below the young adult normal mean

7. History of significantly abnormal ECG or screening 12-lead ECG demonstrating any of the following:

   1. HR > 100 BPM
   2. QRS > 120 msec
   3. QTc > 450 msec
   4. PR > 220 msec
8. Prior (within 28 days prior to Day 1) and/or concomitant use of medications known to prolong the QT/QTc interval
9. Prior use of tamoxifen, other SERMs (eg, raloxifene) or antagonists (eg, fulvestrant), aromatase inhibitor, mammalian target of rapamycin (mTOR) inhibitors, or hormone replacement therapy within 3 months before breast cancer diagnosis
10. Concomitant use of anticancer mediations other than those specified for use by the protocol
11. Prior neoadjuvant or adjuvant endocrine therapy since diagnosis of breast cancer
12. History of treatment for osteopenia/osteoporosis or baseline bone mineral density Z-score ≤ -2.0
13. Prior (within 6 months prior to Day 1) or current use of drugs known to increase bone mineral density (ie, bisphosphonates, denosumab, teriparatide, abaloparatide, romosozumab) or use of supplements known to increase bone mineral density (ie, calcitonin, fluoride, strontium) within 28 days prior to Day 1
14. Low trauma fracture(s) occurring within 12 months prior to subject's first visit (defined as a fracture that results from a fall from a standing height or less, excluding fingers, toes, face and skull)
15. Conditions that preclude bone mineral density measurement (lumbar spine/bilateral hip surgery with hardware in place, abdominal clips, umbilical ring [not willing to remove] or weight that exceeds the DEXA machine limitation)
16. Any other medical condition or serious illness, presence of a second malignancy under current treatment or follow-up, or the presence of clinically significant findings on the physical exam, laboratory testing, medical history (including conditions that may be associated with low bone mass), that in the opinion of the Investigator may interfere with trial conduct, subject safety, or interpretation of study results
17. Already receiving and/or previously received GnRH analogs within 1 year before breast cancer diagnosis
18. Psychiatric, addictive, or other disorders that would preclude study compliance

19. Use of medications that may impact subject safety and/or affect the PK of the drug and hormonal assessments including but not limited to:

    1. Oral or transdermal hormonal therapy within 30 days prior to subject's first visit
    2. Estrogen, progesterone, or androgens within 30 days prior to subject's first visit
    3. Hormonal contraceptives within 30 days prior to subject's first visit
    4. Medications known to result in clinically important decreases in bone mass taken within 6 months prior to subject's first visit
20. Known hypersensitivity, idiosyncratic, or allergic reactions to GnRH, GnRH agonist/analogs or to any of the components of the IP
21. Sexually active with a male partner and not willing to use non-hormonal contraceptive methods throughout the study
22. Is of childbearing potential with a positive serum pregnancy test at Screening or urine pregnancy test at Day 1
23. Exposure to any investigational agent within 30 days prior to the first dose of TOL2506

See contact information to obtain inclusion/exclusion criteria for males

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 49 Years (Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: A Mehta; 919-589-2121 ext 2121; amehta@caidya.com

Contact: C Fajardo; 702-569-6355; cris.fajardo@caidya.com

• Listed Location Countries: Argentina, Brazil, Canada, Mexico, Puerto Rico, United States

Administrative Information

• NCT Number: NCT04906395
• Other Study ID Numbers: TOL2506A
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Tolmar Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: Tolmar Inc.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: E P Hamilton; SCRI Development Innovations, LLC

• PRS Account: Tolmar Inc.
• Verification Date: July 2023